Aclaris Therapeutics (ACRS) Long-Term Debt Issuances (2020)
Aclaris Therapeutics (ACRS) recorded quarterly Long-Term Debt Issuances of -$37000.0 in Q2 2020, down 100.34% quarter-over-quarter from $11.0 million in Q1 2020.
Aclaris Therapeutics (ACRS) Long-Term Debt Issuances (2020) Analysis & Trends
Aclaris Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at -$37000.0 for Q2 2020.
- In Q2 2020, Long-Term Debt Issuances changed N/A year-over-year to -$37000.0; the TTM figure through Dec 2020 stood at $10.9 million (changed N/A YoY), while the FY2020 annual figure was $10.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances was -$37000.0 for Q2 2020 at Aclaris Therapeutics, down from $11.0 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $11.0 million in Q1 2020 to a low of -$37000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -37,000.00 |
| Jun 30, 2020 | -37,000.00 |
| Mar 31, 2020 | 10.95 Mn |
| Mar 31, 2020 | 10.95 Mn |